Clinical Trials Logo

Antineoplastic Agents clinical trials

View clinical trials related to Antineoplastic Agents.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05030077 Not yet recruiting - Clinical trials for Urothelial Carcinoma

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.

NCT ID: NCT04962958 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label,multi-center ,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT ). The objective of this study is to evaluate if the addition of hepatic artery infusion chemotherapy (HAIC) and Donafenib after curative resection for hepatocellular carcinoma patients with a solitary tumor≥5 cm and microvascular invasion (MVI) will prevent or delay the recurrence of the disease.

NCT ID: NCT04807166 Not yet recruiting - Ovarian Neoplasms Clinical Trials

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits. Therefore, this study is expected to investigate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer.